Horizon Therapeutics (NASDAQ:HZNP) has published long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA injection with methotrexate in ACR Open Rheumatology. The 12-month data reinforces key findings shown at Month 6, including the durability of urate-lowering response, reduced infusion reactions, and reduced immunogenicity of pegloticase when co-administered with methotrexate. The patient response rate remained nearly 30 percentage points higher with methotrexate co-therapy during Month 12.